On World Asthma Day 2024, AstraZeneca stands with the severe asthma community to highlight the condition’s profound impact on patients and healthcare systems. Severe asthma is a distinct form of asthma affecting 3-10% of cases, with up to 57% patients having uncontrolled disease. Hear from advocates Poppy and Tonya as they describe the challenges facing patients today. To find out more about Respiratory and Immunology - Our therapy areas - AstraZeneca visit our website. ------------------------------------------------------------ Global site: https://www.astrazeneca.com/ Careers site: https://careers.astrazeneca.com/ Follow us: Twitter: https://twitter.com/AstraZeneca LinkedIn: https://www.linkedin.com/company/astrazeneca/ Instagram: https://www.instagram.com/astrazeneca/ Facebook: https://www.facebook.com/astrazenecacareers/ References: 1. Chung KF, Wenzel SE, Brozek JL, et al. 2014. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43(2): 343-73 2. Hekking PW, Wener RR, Amelink M, et al. 2015. The prevalence of severe refractory asthma. J Allergy Clin Immunol 135(4): 896-902 3. Wang E, et al. Characterization of Severe Asthma Worldwide. Chest. 2020;157(4):790-804.

 1311